Peptides DB
Research-centric peptide and protocol reference hub
Study 23 of 24Teriparatide (PTH 1-34) literatureSpine · Meta-analysis2026

Perioperative Anabolic Osteoporosis Pharmacotherapy Is Associated With Lower Rates of Proximal Junctional Kyphosis After Adult Spinal Deformity Surgery: A Systematic Review and Meta-Analysis.

Anabolic osteoporosis pharmacotherapy may lower the rates of proximal junctional kyphosis and reoperation after spinal deformity surgery, but the evidence is not robust enough to make definitive clinical recommendations.

Read at SpineAdd to compare

Where it sits

this study against the rest of the teriparatide (pth 1-34) corpus
1
Preclinical
18
Observational
0
Open-label
3
Randomised
2
Reviews · this one

Summary and findings

This systematic review and meta-analysis evaluated the association between perioperative anabolic osteoporosis pharmacotherapy and the rates of proximal junctional kyphosis (PJK) and reoperation for mechanical failure in adult spinal deformity surgery. Teriparatide was the primary or sole study agent in nine of the thirteen studies included. The analysis found a reduction in odds for both outcomes associated with anabolic pharmacotherapy.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
PJK odds reduced with anabolic pharmacotherapy, pooled OR 0.51, 95% CI 0.30 to 0.86, P=0.012, I2=0%, k=5.2026

Abstract

The authors’ words, as Spine supplied them

<h4>Study design</h4>Systematic review and meta-analysis.<h4>Objective</h4>To determine whether perioperative anabolic osteoporosis pharmacotherapy is associated with lower rates of (1) proximal junctional kyphosis (PJK) and (2) reoperation for mechanical failure following adult spinal deformity surgery.<h4>Summary of background data</h4>Mechanical complications occur in 15 to 40 percent of patients following adult spinal deformity surgery. Although poor bone quality has been associated with mechanical failure, no quantitative synthesis has tested whether perioperative pharmacotherapy alters these outcomes.<h4>Methods</h4>PubMed, Embase, Scopus, and Cochrane CENTRAL were searched through April 30, 2026 (PROSPERO CRD420261374961). Random-effects meta-analysis was performed for the primary and prespecified secondary outcomes. The primary pool comprised anabolic-exposed studies; a class-agnostic pool that additionally included a single antiresorptive-dominant, claims-based study was retained as a sensitivity analysis.<h4>Results</h4>Thirteen studies (one randomized controlled trial, twelve observational; 2,247 patients) met inclusion criteria. Teriparatide was the primary or sole study agent in nine of thirteen studies. Anabolic pharmacotherapy was associated with reduced odds of PJK (pooled OR 0.51, 95% CI 0.30 to 0.86, P=0.012; I2=0%, k=5) and of reoperation for mechanical failure (OR 0.36, 95% CI 0.14 to 0.88, P=0.025; I2=55%, k=4). A broadened-class sensitivity analysis including the antiresorptive-dominant study was directionally consistent (OR 0.63, 95% CI 0.42 to 0.94, P=0.024). Leave-one-out sensitivity analysis preserved the direction of the PJK effect across all iterations.<h4>Conclusions</h4>Perioperative anabolic osteoporosis pharmacotherapy is associated with lower rates of proximal junctional kyphosis and reoperation following adult spinal deformity surgery, providing the first pooled evidence that the underlying bone-quality substrate may be pharmacologically modifiable. The certainty of this evidence is low; these findings support incorporating bone health optimization into perioperative planning as a modifiable target and prioritizing randomized trials of specific agents.<h4>Level of evidence</h4>IILevel of Evidence: II: Systematic review of cohort studies with one randomized controlled trial.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Teriparatide (PTH 1-34) corpus

BPhenotypic-Genotypic Discordance in Renal Tubular Acidosis with Hypokalemic Rhabdomyolysis and a TRAPPC2 Variant: A Case Reportbiorxiv-preprint · 2023 · n=1 · Serum potassium was 1.7 mmol/L during an acute episode.HumanCCombined Teriparatide and Exercise Effects on Diabetic Skeletal Muscle Ultrastructure.In vivo (Athens, Greece) · 2026 · Not reported in abstract.AnimalDParathyroid Hormone for Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis.Oral diseases · 2026 · Odds ratio 5.81.reviewBReal-World Effectiveness of Osteoporosis Treatments on Bone Strength and the Impact of Sequential Anabolic Therapybiorxiv-preprint · 2026 · 39.5% increase in vertebral strength with Romo at 12 months, n=57, 95% CI [34.2, 44.7]HumanABioengineered acellular tissue engineered vessels versus autogenous fistulae for haemodialysis access: a multicentre, randomised, controlled, phase 3 trial.The Lancet. Digital health · 2026 · n=242 · Global relative patency of 1·17 (95% CI 1·04-1·31, p=0·0090).HumanCAscorbic acid mitigates oxidative structural degradation in bovine spermatozoa: a label-free quantitative phase microscopy study.Veterinary and animal science · 2026 · Not reported in abstract.Animal